Last reviewed · How we verify
NCT01942655: INTESTIPAX
IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection
NA trial testing Blood sample and recto-colic biopsies in HIV Reservoirs in 26 participants. Completed in 1 March 2018.
1 March 2018
Quick facts
| Lead sponsor | ANRS, Emerging Infectious Diseases |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 26 |
| Start date | 1 June 2014 |
| Primary completion | 1 March 2018 |
| Estimated completion | 1 March 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood sample and recto-colic biopsies
Conditions studied
- HIV Reservoirs — all drugs for HIV Reservoirs →
Sponsor
ANRS, Emerging Infectious Diseases — full company profile →
Who can join
Adults 18 to 70, any sex, with HIV Reservoirs. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Progressive HIV or HIV infection seems to be related to a preferential loss of CD4+ T lymphocytes, especially Th17+, within the mucosal intestinal lymphoid tissue, and with intestinal mucosal damage and bacterial product translocation, which correlates with the hyperactivation of the immune system, therefore with CD4+ T cell loss and prognosis. The objectives of this project are to investigate the correlation between the IL12/IL-23 imbalance and bacterial product translocation, and to study the polarization, infection or depletion of intestinal Th17 ex vivo. The investigators will test the effect of neutralizing anti-IL23 antibodies directed against p40, or less classically, anti- IL-23 p19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01942655
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other ANRS, Emerging Infectious Diseases trials
Trials by the same sponsor.
- NCT07098481 — Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy · Phase 4 · not yet recruiting
- NCT06913959 — HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM) · not yet recruiting
- NCT07113106 — Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers · Phase 1, PHASE2 · recruiting
- NCT05222945 — A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Pa · NA · not yet recruiting
- NCT06522256 — Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of H · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01942655 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ANRS, Emerging Infectious Diseases
- Last refreshed: 30 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01942655.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing